List of Imaging Companies in United States - 121

3CPM Corporation is a Medical Technology company that offers a non-invasive 45-minute test using AI-derived patented technology to accurately characterize gastrointestinal motility disorders such as gastroparesis and functional dyspepsia.

3D ultrasound therapy

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Over the past decade, Advanced Brain Monitoring has developed and implemented mobile, user-friendly platforms for acquiring, integrating, analyzing and reporting multi-sensor data in real-world applications. Our strong and growing technical team includes PhD- and masters-level hardware engineers, biostatisticians, software engineers and experts in signal processing, experimental design and clinical trials. ABM seeks to build on existing collaborations within the academic community and develop strategic partnerships across industry with like-minded professionals.

A.I. Analysis, Inc. is a medical software company specializing in the application of artificial intelligence (AI) to radiology. A.I. Analysis, Inc.’s first product is the Change Detector for Brain Imaging, a machine-learning based system that compares serial MR imaging studies and presents changes in the form of a color overlay superimposed on the anatomical images. The Change Detector saves radiologists time at the beginning of their reading — perhaps up to 10 minutes for diseases such multiple sclerosis. The Change Detector highlights the locations of changes and degree of those changes, so the radiologist can more quickly reach clinical judgments. Using the Change Detector, it may be possible for radiologists to detect changes months earlier than is possible with manual inspection alone, with greater reproducibility.

Akrotome Imaging, Inc. is focused on the clinical translation of cancer-targeted molecular probes into enhanced approaches for surgery and diagnostics, leading to improved outcomes and patient quality of life while positively impacting healthcare economics. Akrotome is a Delaware C Corporation with offices in Ohio, Indiana, and California. The company was first incorporated in 2008 and the current management team has been in place since May of 2012. The company's approach stresses the efficient use of capital, coupled with strategies that emphasize the fastest routes to the clinical market with the lowest regulatory overhead.

We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com

Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS).

AngioInsight, Inc. is a digital health company based in Ann Arbor, Michigan, specializing in artificial intelligence for cardiovascular diagnostics. Founded in 2018, the company develops AI-driven solutions aimed at improving the accuracy and efficiency of diagnosing and managing coronary artery disease (CAD). The AngioAI+ platform is a key offering, designed for real-time assessment during angiography. It provides actionable insights by detecting microvascular dysfunction and quantifying stenosis severity. Additionally, AngioInsight offers fully automated angiogram analysis, which processes coronary angiogram videos to support clinicians in making informed treatment decisions. The company's technology integrates seamlessly into existing clinical workflows, enhancing resource allocation and patient outcomes. AngioInsight has received significant funding, including grants and investments, to support its innovative approach. The company is actively engaged in clinical studies to validate its platform's efficacy, particularly in addressing diagnostic gaps in cardiovascular care. Its solutions are targeted at cardiologists and healthcare institutions that perform millions of angiograms annually.

BioDynamic Imaging delivers better drug assessment in three-dimensional (3D) living tissue samples, revealing a comprehensive phenotypic response that is more physiologically meaningful than from conventional 2D or monolayer screens. Our technique is label-free and probes up to 1 mm deep in living tissue to study drug response in heterogeneous tissue environments. BioDynamic Imaging converts all forms of functional cellular motions into contrast maps of cellular mechanisms of action.

Are you ready for a transformative leap in small bowel capsule endoscopy? Meet ProScan, our cutting-edge AI Assisted Reading Tool meticulously designed to revolutionize the diagnostic process for patients suspected of small bowel bleeding. ProScan leverages advanced artificial intelligence algorithms to significantly reduce the time required for reviewing capsule endoscopy studies, enabling quicker and more precise diagnoses. It is meticulously engineered to expedite the evaluation of capsule endoscopy images, enhancing the timeliness of a diagnosis and initiation of therapy. Headquartered in Plano, Texas, AnX Robotica brings versatility in development and integration of multi-discipline technologies such as precise magnetic, robotic control, in house ASIC design, artificial intelligence, micro-optical imaging, image processing, and wireless transmission. With more than 200 patents granted or applications pending, and dozens of clinical papers published in major international journals, AnX Robotica, together with its sister companies, have become the leading companies in robotic capsule technology.

Augmedics pioneers cutting-edge augmented reality technologies to improve surgical outcomes. The company's revolutionary xvision Spine System® allows surgeons to see patients' anatomy as if they have "x-ray vision" and accurately navigate instruments and implants during spine procedures. The first-of-its-kind, FDA-cleared xvision has been used to treat over 4,000 patients and implant more than 20,000 pedicle screws across 21 US states. Augmedics has received numerous honors, including being named a 2021 Index Awards Finalist, a Fast Company World Changing Ideas Awards 2021 Finalist, and one of Time Magazine's Best Inventions of 2020. It was recently featured in The Economist documentary How will businesses use the metaverse? To learn more or schedule an xvision demo, visit augmedics.com.

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in PAD patients.

At Best nomos we design products and solutions that help medical professionals treat a variety of cancers. We are best known for our innovations in IMRT and IGRT. As one of the newest members of the Best family of companies, our aim is to expand our product selection beyond imaging technology to become the Single Source Oncology Solutions provider of choice for our customers.

BioPAL is a biotechnology company that provides novel diagnostic tools to the life science community.

Blaze Bioscience, Inc. is a privately held biotechnology company dedicated to improving the lives of cancer patients, starting with kids undergoing brain cancer surgery. By leveraging our Tumor Paint technology®, including the CANVAS Imaging system® and our CDP Discovery Platform, our goal is to make the detection, removal, and treatment of all cancers sensitive, reliable, and accessible, especially early-stage cancers where cure may still be possible.

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

Butterfly’s mission is to create access to valuable clinical insights using innovative ultrasound technology, made simple with artificial intelligence, to benefit all patients worldwide. Through the delivery of high-quality, affordable, easy-to-use, intelligently connected ultrasound, Butterfly Network enables better clinical decisions through better information and insight at the point of care. With Butterfly, seeing is knowing – in the hospital, community, or home.

C4 Imaging develops innovative medical devices that enable clinicians to personalize patient treatment through accurate image-guided procedures. The company's core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent that has been encapsulated within an implantable, biocompatible shell. C4 Imaging's first product is the Sirius™ MRI Marker, which will be used to facilitate seed localization during the treatment of prostate cancer. The Sirius™ MRI Marker will allow physicians to accurately locate seeds within the complicated anatomy of the prostate and the surrounding critical structures, utilizing a single post-implant MR imaging procedure. C4 Imaging's goal is to improve quality assurance by allowing post-implant seed localization to be performed with MRI alone, eliminating the need for computed tomography in assessment of prostate brachytherapy.

Founded in 1991 as Lucid Technologies, Inc. and later Lucid, Inc., Caliber I.D. offers in-vivo confocal microscopes designed specifically for imaging skin and other tissue. Caliber I.D.Õs Rapid Cell ID technology enables scientists and physicians to characterize intact normal and abnormal cellular architecture that is otherwise invisible to the naked eye.

CapsoVision is a medical device manufacturer based in Silicon Valley, USA. We are engaged in the development of innovative capsule endoscopy (CE) solutions that empower physicians, streamline clinical operations and enhance patient experience. Our novel small bowel capsule endoscope CapsoCam Plus® is the only CE system with a 360° field of view, no capital equipment, and a state-of-the-art CapsoCloud® cloud-based software for efficient image review and analysis.

CellTivity Scientific is a medtech company pioneering real-time, intraprocedural cancer diagnostics through Dynamic Cell Imaging (DCI)—our proprietary technology that visualizes cellular metabolism to assess biopsy adequacy and detect suspicious activity on the spot. Our Mission Empowering the proceduralist to improve patient outcomes through better diagnostic cancer sampling. What We Do Our flagship system, Van Gogh™, delivers instant metabolic “heat maps” of freshly excised tissue—no stains, no cuts, and no delays. Designed for the proceduralist, it fits directly into existing bronchoscopy workflows, empowering clinicians with immediate insights into cellular metabolism at the point-of-care - without altering or destroying tissue samples. This is accomplished by capturing both cellular morphology and metabolic activity to confirm lesion-in-tool, reduce indeterminate biopsies, and improve diagnostic yield at the point-of-care. Why It Matters ⚡ Real-Time Insight: Evaluate biopsy quality instantly, without waiting for pathology. 🔬 Metabolism Illuminated: Capture what traditional imaging can’t—live, functional behavior at the cellular level. 🧠 Proceduralist Empowerment: Eliminate uncertainty mid-procedure and enable data-driven decisions, without disrupting workflow. 🏥 Preserves Tissue Integrity: Samples remain untouched for downstream histology and molecular analysis (e.g., NGS). 📈 Clinically Validated: Proven to increase diagnostic confidence, shorten procedure time, and outperform traditional ROSE.

At CereHealth, our mission is to revolutionize healthcare through the power of artificial intelligence. We are committed to improving patient outcomes and enhancing the efficiency of clinical practices by providing cutting-edge AI-driven Clinical Decision Support Solutions (CDSS). Our purpose is to bridge the gap between data and insights, enabling healthcare professionals to make informed and precise decisions at every critical juncture. By harnessing the potential of AI, we aim to empower medical experts with real-time, evidence-based recommendations that promote accurate diagnoses, personalized treatment plans, and optimize patient care. Driven by our dedication to innovation and integrity, we envision a future where healthcare providers can seamlessly integrate AI into their workflows. Through continuous research, collaboration, and advancements in AI technology, we strive to be at the forefront of CDSS, setting new standards for excellence in healthcare decision-making. We are unwavering in our commitment to privacy and security, ensuring that patient data is treated with the utmost confidentiality and adhering to the highest standards of compliance. Our solutions are designed not only to support medical professionals but also to engender trust among patients, knowing that their well-being remains at the heart of every AI-driven recommendation. By working hand in hand with the medical community, we aim to foster a healthcare landscape where AI augments human expertise, leading to faster, more accurate diagnoses, reduced medical errors, and ultimately, improved patient outcomes. At CereHealth, we are dedicated to shaping a healthier tomorrow through the synergy of AI and medical wisdom.

Clear Guide Medical is a leader in next-gen medical imaging fusion and navigation technology. Our vision-based approach has been introduced in a family of clinical guidance products, including the CLEAR GUIDE SCENERGY for instrument guidance and SCENERGY FUSION for ultrasound and CT/MRI image fusion. Our products make minimally-invasive interventions like biopsies, ablations, pain injections, and peripheral nerve blocks efficient and cost-effective. The company is a privately-held spinout of the Johns Hopkins Medical Institutions and The Johns Hopkins University based in Baltimore, Maryland.

CoapTech is bringing a series of breakthrough medical devices to worldwide markets, leveraging a patented, disruptive platform technology called the Point-of-care Ultrasound Magnet Aligned (PUMA) System. The PUMA Platform will disrupt multiple medical procedures, reducing health care costs, and improving efficiency, safety, quality, patient experience, and access to services around the globe. Invented by Dr. Steven Tropello, a Johns Hopkins-trained critical care physician, the PUMA System enables diagnostic, interventional and therapeutic procedures in hollow organs. The system combines magnetic attraction for device placement guidance, and ubiquitous, low-cost, point-of-care ultrasound for visualization in hollow cavities. Our lead device, the PUMA-G, selected because of its low risk, clear FDA pathway, and strong commercial viability, is for the insertion of Gastrostomy (feeding) tubes. PUMA-G enables a point-of-care (i.e. bedside, as opposed to operating room) procedure for inserting gastrostomy tubes which can be quickly and easily performed by non-surgical providers. By eliminating specialty suites and specialist consultants, PUMA-G will save hospitals money and improve efficiency and safety for this common procedure. PUMA-G has been validated in human anatomy, and has a streamlined regulatory pathway based on FDA presubmission feedback.

Collagen Medical is a healthcare company that specializes in medical products and services related to collagen.

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

DeepHealth is RadNet's AI-powered health informatics subsidiary, created to empower breakthroughs in care delivery. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all data to drive value across the enterprise. DeepHealth aims to elevate the role of the radiologist, beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI technologies in breast, lung, prostate, and brain health, as well as operational efficiencies to create end-to-end efficiency across the enterprise.

Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Called SoftVue™, and featuring proprietary TriAD™ (triple acoustic detection) technology, the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. This is something no other ultrasound system, currently available, can do. SoftVue has received 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Formed in 2010 as a spin-out of Karmanos Cancer Institute in Detroit, MI, Delphinus is committed to creating improved imaging methods that assist medical professionals better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, and without concern of radiation or discomfort.

We manufacture Vision electrophysiology testing equipment for detecting eye diseases and sold mainly to hospital and eye doctors. Based in the USA, we create the leading solutions for electrophysiology for all your needs in hospitals, research and drug trials

EchoNous creates transformative handheld point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools providing more clinicians with increased information faster. Visit our website at https://www.echonous.com/ Explore a directory of our most popular content https://linktr.ee/echonous.kosmos

Edan is a healthcare company dedicated to improving the human condition around the world by delivering value-driven, innovative and high-quality medical products and services. For over 20 years, Edan has been pioneering a comprehensive line of medical solutions that address a broad range of healthcare practices including Diagnostic ECG, OB/GYN, Ultrasound Imaging, In-Vitro Diagnostics, Patient Monitoring, Point-of-Care Testing, and Veterinary. Healthcare professionals around the world depend on Edan's breakthrough medical technologies and outstanding customer support. Till now, EDAN has reached over 170 countries and areas and 40,000 medical facilities with Industry Leading Healthcare solutions.

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit www.bostonscientific.com and connect with us on X, Instagram, and Facebook. At Boston Scientific, you will find purpose, a place to grow and opportunities to cultivate your passions. To search and apply for open positions, visit https://bostonscientific.eightfold.ai/careers. You may also review our social media guidelines at http://www.bostonscientific.com/social.

ENDRA Life Sciences Inc. ("ENDRA"​) (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com. Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100B annually. NAFLD is often asymptomatic and, If left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.

Escalon, operates in the healthcare market, develop, manufacture, marketing, and distribution of medical devices for use in ophthalmology.

Femasys is a biomedical company focused on transforming women's healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys' FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician's office setting.

From the beginning Sonosite has been dedicated to empowering clinicians to continue innovating the practice of medicine for the sake of providing better patient care. They continue to partner with clinicians to bring the benefits of ultrasound to the point-of-care.

Genetesis is a rapidly growing medical imaging company leveraging data science and biomagnetism in the fight against cardiovascular disease.

Based in Sudbury, MA., Gentuity is a commercial-stage medical technology firm dedicated to developing next-generation intravascular imaging devices capitalizing on today's best-in-class technologies. Gentuity was founded on the principles of advancing patient care, improving outcomes, and expanding the utility of intravascular procedural guidance tools in the realm of cardiovascular disease. The Gentuity High-Frequency OCT Imaging System is the first commercially available OCT imaging system to deliver Total Vessel Imaging with the first 1.8F micro-imaging catheter. Gentuity and its' next-generation platform are paving the way for transformation in the intravascular imaging world. Designed to support the growing needs of the imaging industry, the platform incorporates AI and machine learning with the intention of creating "collaborative intelligence" to enhance ease of use and procedural success.

Gynesonics is a medical technology company that specializes in providing minimally invasive solutions for women's health, particularly in the treatment of uterine fibroids.

Vista.ai is harnessing the power of artificial intelligence (AI) to offer clinicians an easy, cost-effective and stress-free way to conduct MRI studies. The company's FDA 510(k) cleared MRI CoPilot™ software-only solution automates and dramatically simplifies a CMR exam, enabling any MRI tech to perform a CMR in a standard mixed-use scanner time slot. Available for use on Siemens Healthineers and GE Healthcare MRI scanners, MRI CoPilot™ • Eliminates the need for specialized CMR technologist • Allows CMRs to fit into your mixed-use scanner standard time slot • Makes scans less stressful for the technologist • Gives patients greater comfort and convenience Vista.ai is funded by Khosla Ventures, and the National Institute of Health's Small Business Innovation Research program.

Established in 1996 and located along Route 128 in MA, HAI Laboratories, Inc. is the only American manufacturer of clinical, eye bank and laboratory specular microscopes in operation today. We are also known for our advanced software systems for image processing and analysis, digital video slit lamps and high quality ophthalmic microsurgical instruments.

Surgical Planning Associates, Inc. is a medical technology company based in Boston, Massachusetts. They developed the HipInsight System, a mixed reality-based digital surgery platform specifically for total hip arthroplasty. This system is notable for being the first FDA-cleared mixed reality navigation technology for hip surgeries. The HipInsight System utilizes Microsoft HoloLens 2 to provide surgeons with real-time holographic visuals of patient-specific anatomy, instruments, and implants. It enhances surgical precision through personalized planning and intraoperative guidance, seamlessly integrating into existing surgical workflows. The system is compatible with Zimmer Biomet's premier hip implant systems, and the company has successfully supported over 11,000 hip replacement surgeries globally.

The Swoop® system brings MR brain imaging within reach. Our mission is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world's first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020. It is a portable ultra-low field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

At iCAD, we believe that is possible to create a world where cancer can't hide. Leveraging the power of artificial intellegence (AI), we empower healthcare providers to more accurately, reliably, and quickly detect disease and improve outcomes. The ProFound Breast Health Suite offers a comprehensive portfolio of clinically proven AI technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation providing certainty and peace of mind - Optimizing every patient's opportunity to live better, longer lives! To learn more, visit www.icadmed.com.

Ikonopedia is a next-generation breast radiology reporting and patient tracking system. Our closed-loop system is automated to track and monitor patients to full resolution of all clinical concerns. Clinical reports are clear, consistent, and 100% compliant with the ACR BI-RADS® Atlas 5th Edition. Ikonopedia is MQSA-compliant and offers screening and diagnostic modalities that will improve patient safety and save valuable time for the radiologist and staff.

Enhance Productivity and Quality with Reporting Automation and Ultrasound Reading Tools Imorgon provides innovative solutions for Radiology reporting automation and ultrasound reading. Our tools dramatically improve the efficiency and quality of creating structured reports. Ultrasound Reporting Software: Measurement Transfer: Our tools extract measurements from various imaging modalities, including ultrasound, CT, and DEXA, from DICOM SR and other structured files. These measurements are parsed and seamlessly inserted into a reporting package, enabling the creation of structured reports more efficiently and with higher precision. Electronic Worksheets: Imorgon offers customizable electronic worksheets that allow technologists to capture exam findings consistently and quickly. These findings can be automatically integrated into the report, eliminating the need for a Radiologist to dictate them. This approach is superior to traditional solutions that store worksheet images in PACS and require Radiologist re-entry. Together, DICOM SR and electronic worksheets form a comprehensive ultrasound reporting solution. Ultrasound Reading and PACS: Many PACS viewing stations provide an inflexible and suboptimal exam review experience. Imorgon addresses these limitations by offering advanced features. Our platform enables the display of ultrasound images and clips in interleaved, acquisition order with automatic clip playing. Additionally, our Sonographer QC Workstation empowers sonographers to correct patient and study information, split or merge studies, delete images, add or edit annotations, and make measurements. These capabilities enhance efficiency and accuracy in ultrasound reading. Integration: Imorgon seamlessly integrates with enterprise PACS, HIS/RIS, and reporting systems, ensuring a smooth workflow and compatibility with existing infrastructure.

Indica Labs is a digital pathology company that specializes in advanced software solutions for medical imaging and analysis in the field of healthcare technology.

There are still broad swaths of uncharted territories concerning the role lipid core plaques play in heart disease. Now, you can achieve unparalleled insights with the Infraredx Dualpro IVUS+NIRS catheter and its accompanying Makoto Intravascular Imaging System, FDA-cleared to identify patients and plaques at an increased risk of MACE. For more information about the Makoto Imaging System or Dualpro IVUS+NIRS Catheter visit www.infraredx.com. Infraredx, a Nipro Company is now proud to offer the OKAY II Y-Connector to the US market. The number one selling Y-Connector in Japan is now available. Visit www.infraredx.com/technology/nipro-okay-ii/ to learn how you can reduce blood loss with the OKAY II Y-Connector.

InkSpace Imaging Inc. is a medical device manufacturer that specializes in innovative magnetic resonance imaging (MRI) technology. Founded in 2017 by researchers from UC Berkeley, the company aims to enhance patient comfort and diagnostic efficiency with its lightweight and flexible MRI-receive coils. Their mission focuses on transforming MRI experiences for both healthcare providers and patients by prioritizing comfort, performance, and cost-effectiveness. The company produces featherlight, flexible MRI coils suitable for 1.5T and 3T MRI systems. Notable products include a 24-channel body array designed for pediatric patients, featuring a dinosaur-themed design to help reduce anxiety. These coils are adaptable to various body shapes and sizes, offering 360-degree coverage and positioning freedom. InkSpace's proprietary printed technology allows for low-cost manufacturing of coils that conform closely to anatomy, minimizing the need for sedation in pediatric imaging. The company also emphasizes patient-centered design and technical support to improve MRI workflows and patient throughput.

Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery. Integro Theranostics was born out of a collaboration between Kingdom Capital (values based private investment company) and Washington University School of Medicine. We are combining the clinical infrastructure of a top research medical center, the technology of a world renowned scientist, and the resources of Kingdom Capital to commercialize this transformative technology and improve surgical outcomes for cancer patients.

Invenio Imaging is a medical device start-up based in Santa Clara, CA dedicated to advancing the care of cancer patients by combining intraoperative histologic imaging with artificial intelligence. Our technology, the NIO® Laser Imaging System has been used in over 2500 cancer treatment procedures at major cancer centers both in the US and in Europe. In 2021 Invenio received a Medical Design Excellence Award, was selected to be a Rosenman Innovator and received CE Mark to commercialize in Europe.

The iSono Health has developed the world’s first AI-driven platform with an automated, portable, and wearable ultrasound to empower women and their physicians with early breast cancer detection and monitoring. Our patented compact ultrasound scanner captures 3D images by automatically scanning the whole breast volume in 2 minutes. The device connects to a smartphone/tablet/laptop. The data is transferred to a secure cloud for image processing and storage. Our machine-learning algorithm uses acoustic biomarkers to identify abnormal masses. Our platform’s automated operation and software expand ultrasound use in point-of-care diagnostics and monitoring of breast health at radiology centers, walk-in, and mobile clinics. iSono Health offers women and healthcare providers : Safety: No Radiation Actionable Feedback with AI Fast: 2min Scan Easy to Use

IZI Medical is a prominent medical device manufacturer and distributor, specializing in minimally invasive diagnostic and therapeutic solutions. Founded in 1991 by a neuroradiologist and a radiation oncologist, the company is headquartered in Baltimore, Maryland. In 2022, IZI became part of Halma plc, operating as a standalone entity within Halma’s Healthcare sector. The company is dedicated to enhancing patient care through physician-inspired innovations and aims to improve the quality of life for patients. IZI Medical offers a diverse portfolio of 44 medical devices across four key markets: image-guided surgery, interventional oncology, interventional neuro and spine, and radiation therapy. Their products include tools for instrument navigation, tumor localization, and treatment planning systems. With over 100 active patents, IZI Medical emphasizes innovation in minimally invasive procedures. The company serves more than 2,500 hospitals in the U.S. and distributes its products to physicians in 35 countries, focusing on improving clinical efficiency and patient outcomes.

JuneBrain is an early start-up company based in the Washington, DC area. Our mission is to develop a telehealth eye-scanning system that allows clinicians to monitor patients with eye and brain disease outside of the traditional clinical setting, leading to earlier detection of new disease and improved monitoring of treatment efficacy. Though our mission begins in the eye care community, our long-term goal is to extend the use of our device into the broader neurological disease population, thus creating a pathway towards more frequent, widely accessible monitoring of eye and brain health.

Koning Corporation develops and manufactures advanced medical imaging systems for breast cancer detection using cone-beam computed tomography technology. This revolutionary technology provides true 3D images for early breast cancer detection, providing a significantly more accurate and effective test than mammography and tomosynthesis. Koning's vision is to fundamentally change breast cancer is detected and diagnosed, with earlier detection, increased patient comfort and lower costs. We believe our Koning Breast CT will dramatically improve the way clinicians visualize and evaluate breast tissue. We believe that the power, versatility and lower cost of Koning Breast CT will serve as a viable substitute for many traditional imaging applications. Our hope is to be able to improve survival rates and outcomes for millions of patients. Koning Corporation's core technologies are protected by over 80 patents globally, and has received regulatory approval in the US (FDA), Europe (CE-Mark), China (CFDA), Australia (TPG), and Canada (Health Canada). Koning has been the beneficiary of over $17 M in venture funding and over $20 M in government grants to bring this exciting technology to market. Future versions of our technology are expected to optimize early disease detection, diagnosis, intervention and treatment in numerous areas of the body.

Laza Medical is a healthcare technology company based in California, founded in 2020. As a portfolio company of Shifamed, it focuses on developing innovative solutions for cardiovascular interventions. The company specializes in AI-powered robotic assistance technology, which enhances medical imaging and procedures. Laza Medical's main offering is an advanced imaging solution that supports cardiovascular interventions. This solution utilizes AI and robotic technology to provide navigation tools for structural heart and electrophysiology procedures in cath labs. The company aims to improve the precision and efficiency of these medical procedures through its technology. In December 2023, Laza Medical raised $36 million in a Series A funding round, led by The Capital Partnership, with participation from investors like Unorthodox Ventures and GE Healthcare Financial Services. With its innovative approach and strong funding support, Laza Medical is positioned to make a notable impact in the medical technology field.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications. The company aims to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind.

We design quantitative imaging software for stereology, neuron reconstruction, and image analysis, integrated with the world's leading microscope systems, to empower your research. Our development team and staff scientists are actively engaged with leading bioscience researchers, constantly working to refine our products based on your feedback and scientific advances in the field. Whether you are interested in design-based stereology, neuron reconstruction, brain mapping, virtual slides, or autoradiography, you can be confident that our products include the most current protocols available to keep you on the cutting edge with accurate results.

MedCognetics provides an advanced AI software platform which integrates into the radiology workflow. The AI platform is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating more predictable medical outcomes and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com.

MedGyn Products manufactures and distributes medical devices for the women's healthcare industry including disposables, high quality instruments and equipment to OB/GYN professionals around the world. Our focus on our corporate values has allowed us to continually grow for over two decades as one of the leading suppliers of medical devices for women. Commitment to Innovation We are continually evaluating our product portfolio to drive innovation in healthcare delivery for women. We focus on innovation by leveraging our relationships with professionals to understand procedural techniques and new product development opportunities. As a result, we have received numerous awards and hold several patents on our products. Commitment to Patients and Professionals We are committed to patients and professionals by constantly evaluating procedural techniques to identify products that are less invasive and more effective on women. Our focus is to improve the quality of life for female patients by offering the best medical device technology. Commitment to Our Diverse Team We have a dedicated employee base that is passionate about improving women's health. We strive to provide a collaborative environment to help our employees succeed. We also continually invest in education and training our team to improve our ability to provide superior customer service.

Meditrina is an innovative start up Company located in San Jose, CA, and founded in 2016 developed the Aveta™ hysteroscopy suite which was designed to provide physicians with the best care in their diagnosis and treatment of endometrial polyps and uterine fibroids. The system seamlessly integrates into any operating, procedure, or exam room. This new hysteroscopy system is an all-in-one platform which includes the single-use Aveta™ Pearl Hysteroscope for myomectomy, and the single-use Aveta™ Coral Hysteroscope for polypectomy procedures with integrated tissue resection and fluid management capability. The Aveta™ Pearl Hysteroscope is the first single-use hysteroscope to include full physician control providing proprietary fluid management and video control function directly on the hysteroscope handle.

As a global healthcare company, we understand customer needs and innovate and deliver medical solutions that transform patient care. Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 300 individuals. Merit employs approximately 6,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.

MinXray, Inc. is an independent corporation founded in 1967 that is dedicated to providing compact, portable and mobile x-ray equipment and digital imaging systems where larger units would be impractical or too costly to use. Currently supplying the medical, veterinary, global health, and military imaging markets worldwide, our field transportable digital x-ray systems represent the cutting edge in advanced electronic design. MinXray imaging systems are the ideal solution for mobile imaging providers who perform onsite imaging in nursing homes, prisons, athletic events, remote clinics, or anytime it is more convenient to bring the imaging system to the patient. All units are compatible with conventional and digital imaging modalities.

NanoCytomics is a biotechnology company that offers PWS Screening for the early detection of various high incidence cancers, providing a simple and effective process for physicians and patients.

Navigation Sciences™ is a clinical-stage company developing the NaviSci™ System for the tissue conserving removal of lung cancer and other soft tissue tumors. The system integrates Augmented Reality (AR) and advanced software with surgical instruments to guide precise surgical resection by enabling for the first time, real-time in-vivo margin measurement. The system aims to improve surgical outcomes with cutting-edge technologies that – reduce recurrence risk and conserve lung function – shorten hospital length of stay and enhance surgical workflow.

NeuraSignal is a medical technology company based in California that specializes in advanced cerebral blood flow assessment. The company focuses on non-invasive solutions for neurological conditions such as stroke, traumatic brain injury, and dementia. NeuraSignal employs robotics, artificial intelligence, and cloud-based analytics to enhance patient care and improve clinical outcomes. The flagship product, NovaGuide Intelligent Ultrasound, is an FDA-cleared robotic transcranial Doppler system. It features innovations like Automated Depth Walk for precise data collection, Multi-Vessel Search for efficient assessments, and Automated Snapshots to capture critical data points quickly. NeuraSignal also offers a cloud-connected platform that allows healthcare providers to access data remotely, stream live exams, and collaborate effectively, supporting real-time decision-making. NeuraSignal serves healthcare providers in neurology, critical care, and emergency medicine, focusing on those managing complex neurological conditions. The company is committed to adhering to regulatory standards to ensure the safety and efficacy of its solutions.

NeuroOne Medical Technologies is a medical device company that specializes in developing high-definition, minimally invasive thin film electrodes for the diagnosis and treatment of various neurological conditions.

Noah Medical is a medical technology company based in San Carlos, California, founded in 2018. The company specializes in developing advanced medical robotics aimed at enhancing diagnostic procedures in pulmonology. Its flagship product, the Galaxy System, is a robotic platform that integrates real-time navigation, augmented fluoroscopy, and tomosynthesis to improve the accuracy of lesion localization, which is vital for early lung cancer diagnosis and treatment. With a team of over 150 engineers and industry experts, Noah Medical leverages extensive experience from leading healthcare companies. The company's mission focuses on saving lives through early diagnosis and treatment, particularly in robotic navigated bronchoscopy. Noah Medical has received recognition as a "Fierce 15" company of 2023 and has raised $150 million in funding to support its innovative approach. Its technology is designed to enhance procedural efficiency and diagnostic accuracy in healthcare facilities, particularly in pulmonology and oncology.

nView medical, based in Salt Lake City, UT, is a startup whose mission is to make surgery safer, faster, and consistently accurate. nView develops imaging technology — bringing breakthrough AI solutions for image creation, image processing, and image visualization to surgery and interventional radiology. nView medical backers include the National Science Foundation (NSF), the National Institutes of Health (NIH), the State Of Utah, the National Capital Consortium for Pediatric Device Innovation, MedTech Innovator, HealthTech Arkansas, Dr. Kevin Foley, M.D., and Fusion Fund (Palo Alto, CA). Its founder, Cristian Atria, has had a progressive career with GE Healthcare in positions that range from development engineer to general manager with P&L responsibility. He has successfully assisted start-up and public companies with technology transfers, licensing, product development, regulatory approvals, and commercialization.

NX PharmaGen develops blood-based molecular diagnostic testing products.

Ocutrx Technologies, Inc. is a high-tech company that specializes in augmented reality (AR), extended reality (XR), and 3D visualization technologies. They develop innovative solutions for various sectors, including medical, military, consumer, and enterprise applications. Ocutrx aims to enhance how users interact with visual data, focusing on improving situational awareness and accessibility for visually impaired individuals. The company offers several products, including the OcuLenz AR/XR headset, which assists patients with advanced macular degeneration and is also suitable for gaming and telemedicine. Their ORLenz system enhances surgical visualization, allowing surgeons to interact more effectively with patient data. Ocutrx also provides customizable AR/XR platforms for developers and enterprises, promoting productivity and immersive experiences. Ocutrx serves a diverse range of customers, including healthcare professionals, military personnel, and developers creating AR/XR applications. The company holds over 25 patents related to AR/XR innovations, particularly in healthcare, showcasing their commitment to advancing technology in this field.

OD-OS aims to set new standards of care for retina treatment. By extending our innovative Retina Navigation platform, our goal is to become the global leader in novel therapeutic solutions for the growing number of people suffering from retina diseases. Join the Navilas mailing list: https://tinyurl.com/od-os-mailing-list Follow us on Twitter: https://twitter.com/OD_OS_Navilas Privacy Policy Social Media Pages: https://www.od-os.com/legal-notice-container/privacy-policy/social-media

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

Visionix is the global manufacturer and exclusive sales, service and training provider for Optovue OCT, Visionix screening and refraction systems, as well as Briot and Weco lens finishing equipment in North America. We are the pioneer in integrating core refractive, screening, and imaging technologies to address the ever-changing needs of eye care professionals in this dynamic market. Today, we are proud to offer high-speed OCT and OCT-A technology designed to facilitate diagnosing and managing a range of ocular diseases. Our goal is to improve access to a complete suite of advanced visual health solutions that transforms the patient experience. With over 100 years of innovation, an expanded product line, as well as a new level of support, clinical education, and practice integration, we are well-positioned to help you unlock your potential. *Not all products, services, or offers are available in every market, and approved labeling and instructions may vary from one country to another.

As a global leader in digital pathology, OptraSCAN is dedicated to revolutionizing diagnostics and patient care through advanced technology. We specialize in providing cutting-edge digital pathology solutions, including state-of-the-art digital pathology scanners and whole slide imaging scanners, designed to enhance the accuracy and efficiency of diagnostic processes. Our extensive range of digital slide scanners includes brightfield slide scanners, histology slide scanners, and fluorescence slide scanners, enabling healthcare institutions to transition seamlessly from traditional microscopy to sophisticated digital pathology systems. Our whole slide scanners and digital pathology slide scanners offer high-resolution imaging that improves precision, streamlines workflows, and provides cost-effective results. OptraSCAN leads the way in digital histopathology with innovative solutions that integrate advanced artificial intelligence (AI). Our AI-powered pathology scanners and digital pathology artificial intelligence technologies are designed to boost diagnostic accuracy and efficiency. We offer comprehensive solutions including whole slide imaging scanners and computer-aided region detection systems. We are committed to making digital pathology accessible to all, providing compact and advanced scanning systems that overcome barriers to modern diagnostic methods. Our digital pathology solutions include cloud-based LIMS (CLOUDPath), image analysis tools (OptraASSAYS), and up to 10 TB of complimentary cloud storage. By choosing OptraSCAN, you partner with a leading digital pathology company that is shaping the future of diagnostics with high-quality digital pathology scanners and integrated whole slide imaging solutions. Our goal is to ensure that healthcare systems worldwide can seamlessly adopt and benefit from our transformative digital pathology technologies.

Orthoscan Inc. is an American company based in Scottsdale, Arizona, founded in 2002. It specializes in orthopedic imaging solutions, focusing on the development and manufacturing of high-quality imaging devices, particularly mini and full-size C-arms. These devices are designed for surgical and clinical imaging, emphasizing advancements in dose reduction, mechanical design, and image quality. The company is dedicated to supporting the American economy by employing U.S.-based workers and sourcing parts locally. Orthoscan's product lineup includes portable mini C-arms for diagnostic purposes and full-size C-arms for more extensive surgical procedures. Additionally, they offer a mobile diagnostic imaging model tailored for clinic use, ensuring ease of portability and operation. Orthoscan's products are utilized by a diverse range of medical facilities worldwide, including clinics, hospitals, and surgery centers.

Overjet is the world-leader in dental AI. Founded by experts from MIT and Harvard University, Overjet builds artificial intelligence that helps dental organizations give patients the highest quality of care. Our FDA-cleared technology is the first objective standard for making oral health decisions — so that dentists can detect pathologies with precision and educate patients with confidence.

Perimeter Medical Imaging AI is a pioneering medical technology company driven to transform cancer surgery with advanced imaging tools. We can't imagine how frustrating it is for surgeons to do everything they can and still have to make the "dreaded call" to the patient. That's why we developed our OCT technology that provides 10x the resolution of X-ray and ultrasound at 2mm imaging depth for real-time insight, so surgeons can act in the moment with greater certainty. A Toronto-based company established in 2013, with U.S. headquarters in Dallas, Texas, Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further our mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.

For over 50 years, PSI has provided technology solutions and innovative products to our government and commercial customers. Our employee-owners continue to grow the company across a range of markets applying emerging science to important problems. We play an important role in the development and transition of advanced technology from the laboratory to commercial and government use. PSI has a highly interdisciplinary staff with advanced degrees in chemistry, biology, physics and applied physics, electrical, aeronautical, and mechanical engineering, and materials science. We are structured to enable cross-disciplinary collaboration between our scientists and engineers in order to develop solutions to our customers' technical problems. Our extensive laboratory and prototyping facilities as well as low rate production capability enable us to rapidly go from concept to advanced prototype, and then on to manufacturing. We couple this internal capability with our long heritage in field and clinical testing of prototype systems enabling us to gain valuable feedback leading to rapid improvement.

Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercializing innovative imaging solutions with its noninvasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.

Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron's innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine. Positron's Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron's PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron's PET-CT systems will enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine. Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co a subsidiary of Neusoft Medical Systems. Positron was founded in 1983 and is based in Niagara Falls, NY.

Precision Image Analysis (PIA) is an innovative, cloud-based image post-processing service delivering analysis, reports and expertise at lower cost with improved consistency through standardization and greater efficiencies in workflow. "The cost and value of PIA services is consistently better than that of purchasing and maintaining specialized software especially when considering the need to train staff to effectively and efficiently interact with that software."​ ~ Dr Michael Wheat Attending Physician, Cardiologist Porter Hospital PIA offers CT and MRI post-processing services to the healthcare and research communities with specific expertise in Cardiac, Vascular and Neuro. Advanced medical imaging often needs time-consuming post-processing by experienced experts. This requires costly software, hardware and extensive training for personnel. PIA provides advanced medical imaging post-processing as a service. Why Outsource Image Post-Processing? --Immediate Access to Advanced Imaging Analysis, Reports & Experts -- PIA specializes in CT & MRI post-processing with specific expertise in Cardiac, Vascular and Neuro post processing. --No Capital Costs - Hospitals and diagnostic imaging centers are under continued pressure to bring down capital expenditures. --No Hardware, Maintenance or Upgrade Costs - High value post-processing WITHOUT costly ongoing fees & overhead also associated with employee retention, training and certification. --It's a service - PIA provides image post-processing as a service to hospitals, diagnostic imaging centers and researchers with no training required. --We never go on vacation. When planning for your medical image post-processing needs, think of PIA as your outsourced expert. Let us show you how we can improve your WORKFLOW and CASHFLOW. Visit www.piamedical.com or contact us at (425) 822-8199 | info@piamedical.com.

PROCEPT BioRobotics is a medical robotics company that specializes in minimally invasive robotic surgery technology.

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' experiences and outcomes. The Promaxo MRI system is designed for image-guided interventions including live MRI guided biopsies, treatment planning, robotic surgeries, and radiation.

The QTI team has been on an incredible journey, starting with a shared mission to create disruptive innovation to expand access to medical imaging while ensuring superior patient experience and improving health outcomes. We anchor our efforts in medical imaging because when the body can be scanned often and without harm, health conditions can be detected before symptoms appear. Chief among the new advancements in medical imaging is 3D body imaging. Today QTI focuses on our breast imaging technology, which is native 3D, high resolution, and generates reproducible image quality regardless of operator or breast size or tissue type. Current breast imaging paradigm leads to unnecessary concern and cost. ▪️Unlike mammography, QTI technology is effective in screening women with dense breasts, or 40% of women in US. ▪️35% of women aged 40-70 do not get screened. Of the 65% of women who get screened, 15% suffer unnecessary callbacks for ultrasounds, MRI, or biopsies. 80% of biopsies are benign. ▪️QTI’s technology can be a much-needed alternative for high risk women under 40, as cancers in younger women are usually aggressive and survival outcomes are poor. Our QT Imaging Breast Acoustic CT™ Scanner is the only true 3D imaging device, FDA cleared for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. There is no ionizing radiation or compression like in mammography or contrast dyes injections like in MRIs. The technology uniquely quantifies breast density. Surface-to-volume ratios and volumetric doubling time growth rate can be calculated to determine significance of lesions and improve specificity. This breast scanning system gives women the choice they deserve to ensure their breast health over time; for healthcare providers, a technology that is accessible, affordable, and accurately visualizes internal structures of the breast; and, for investors, a market segment extension and a purposeful investment opportunity.

RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from over 10 million scans in more than 2,000 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI — where AI meets patient care.

The company uses biology-guided radiotherapy to detect and respond to signals emitted from cancer cells, and use them to guide treatment.

RetiVue LLC is focused on providing novel, high definition retinal imaging technology with a wider field of view to help document early eye disease to help needless blindness. The RetiVue WF Desktop and RetiVue WF Portable are the first affordable non-mydriatic widefield retina cameras for everyone from babies to adults. Our revolutionary design allows you to image up to ten times more of the retina than competing devices. Point and shoot automatic image capture gives you perfect images of the eye every time, regardless of level of expertise. Our company strives to become the de-facto standard equipment used for eye screening, capturing higher quality images, while simultaneously maintaining device affordability and simplifying ease of use.

RIVANNA® is elevating global standards of care through the development and commercialization of world-first imaging-based medical technologies, including BoneVision™ Multi-Probe Multi-Angle Image Acquisition, BoneEnhance® Multi-Frequency Image Reconstruction, and SpineNav3D™ AI-Enabled Spine Recognition. RIVANNA's complete clinician-assistance solutions improve decision-making, workflows, health outcomes, and patient satisfaction. Headquartered in Charlottesville, VA, RIVANNA is privately held and operates an FDA-registered and ISO 13485:2016 certified manufacturing facility. For more information, visit rivannamedical.com.

Tracking System for MRI Guided Interventions

Sanovas, Inc. is a life science asset holding company that is developing and accelerating companies that create medical technologies which are advancing the next generation of minimally invasive surgical tools and technologies.

SCARLETRED is the worldwide leader in standardized skin imaging and AI powered objective skin analysis. We develop and deliver cutting edge software products and services to biopharma-, biotech- , cosmetics companies, clinical research organisations and health care experts. Our certified, ICH-GCP and EU-GDPR compliant mobile medical device software Scarletred® Vision is the first digital solution solving the problem of lacking standardization and subjective visual skin assessment in pre-clinical, clinical, and post-marketing studies. The highly scalable software platform works infrastructure as well as location independent and enables on-site and home-based monitoring of dermatologic disease as well as digital analysis of skin drug related effects. It it easy to use and reduces development time and opportunity cost in clinical RnD projects. Our digital Products and Services are delivered worldwide from our offices in Europe and USA via flexible Software as a Service (SaaS) agreements.

Seno Medical is leading commercialization efforts in opto-acoustic imaging of breast cancer. Seno's opto-acoustic technology combines both laser optics and conventional ultrasound technology to provide fused functional and anatomical imaging in real time. The result is an imaging device that delivers additional functional information regarding breast masses and increases confidence in making a breast biopsy decision. For more information or to answer any questions call 210-615-6501 or email digitalmarketing@senomedical.com. Seno's Imagio® Breast Imaging System (9005) received the CE Mark (April 2014) and has completed a post-market surveillance and clinical follow-up study in Europe. The newest version (9100) is approved by the FDA for commercial distribution in the U.S.

Siemens Healthineersenables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare.COVID-19: CE mark for its molecular Fast Track Diagnostics (FTD)SARS-CoV-2 Assay.

SkinCure Oncology is the only company offering GentleCure™—the most comprehensive approach to delivering advanced, nonsurgical treatment for basal cell carcinoma, squamous cell carcinoma, and other skin cancers using Image-Guided SRT. The company partners with quality-focused dermatologists and Mohs surgeons to bring cancer center-level radiation therapy to physician offices. From clinical, administrative, and operational backing to robust patient support, SkinCure Oncology ensures that practices are fully equipped to offer treatment with Image-Guided SRT. This advanced technology delivers calibrated doses of X-ray energy via the Sensus SRT-100 Vision™, the first and only skin cancer treatment platform with high-frequency ultrasound imaging. Adaptive radiotherapy protocols destroy malignant cancer cells while preserving healthy tissue surrounding the treated areas for optimal clinical and cosmetic outcomes and the ideal patient experience.

Sonavex, Inc. is a Baltimore-based medical device company originally spun out of Johns Hopkins focused on Empowered Patient Care. The company has developed a portfolio of novel ultrasound solutions that empower patient care by delivering critical visual and quantitative data to improve outcomes and reduce costs. EchoMark is a bioresorbable and highly echogenic (visible under ultrasound) implant used to mark at-risk blood vessels such that the site can be easily assessed for future complications. EchoSure is a deep-learning enabled 3D automated ultrasound device designed to be used by healthcare providers without ultrasound training to assess blood flow and morphology of vessels marked by the implanted EchoMark device. For more information, please visit http://www.sonavex.com

Sonivate Medical develops and manufactures technologies to reduce healthcare costs and expand access to diagnostic imaging.

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the Unknown®" with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of changing the current standard of care in the future, DeepView® is expected to provide faster and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

Spectrum Dynamics is spearheading the transformation of Nuclear Medicine from analog to digital technology, enabling clinicians to provide superior healthcare services with improved image quality and efficiency at lower doses. D-SPECT®: The world's first digital cardiac SPECT system based on Broadview Technology: swiveling CZT digital detectors. It is the platform for advanced applications such as TruCorr Attenuation Correction, TruFlow 3D dynamic SPECT imaging for Myocardial Flow Reserve (MFR) analysis, Simultaneous Dual Isotope Imaging (SDI). TruCorr: a deep learning application to generate attenuation corrected myocardial perfusion images. There is no need for additional CT transmission scan, as TruCorr utilizes the SPECT scan emission data. VERITON-CT®: The world's first digital 360°CZT-based, ring-shaped gantry design SPECT/CT, with high-resolution 16 or 64 slice CT. It’s 80cm wide bore accommodates patients of all sizes. VERITON features TruFlow 3D dynamic SPECT/CT imaging for SPECT MFR, bone, renal, and general studies. VERITON-CT continues to evolve with an energy range up to 400 KeV and multiple peak imaging, providing highest quality and quantitation-ready images.

STAGE, developed by SpinTech, is an advanced MRI imaging software platform that reduces brain scan time by 30%. The software provides enhanced visualization and quantification of scan images. STAGE automatically detects biomarkers critical to proper diagnosis of neurological conditions that cannot be seen with current MRI techniques (i.e. traumatic brain injury, dementia, Parkinson's, Multiple Sclerosis, and stroke). We're committed to bringing the future of imaging technology to every patient suffering from neurological disease with a cost effective, workflow-efficient software platform that improves patient outcomes and maximizes costly imaging equipment ROI. STAGE software is compatible with most manufacturers' existing equipment. Visit our website to learn more and set up a demo!

Advancing cerebrovascular care through groundbreaking neuro intravascular imaging and AI technologies.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

Subtle, Inc., is a medical imaging software company. Our goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. We use the state-of-art proprietary deep learning AI algorithms to renovate the radiology workflow to deliver faster, safer and smarter solutions for imaging exams.

Summit Biomedical Imaging, LLC., a spin-off company from Memorial Sloan Kettering Cancer Center (MSK, New York City), was founded by Thomas Reiner and Christian Brand in 2016. Recently, Summit Biomedical Imaging was awarded a federal grant through NIH's Small Business Innovation Research (SBIR) program, also known as America's Seed Fund, to support the strong potential of commercialization of their innovative biomedical technology. This early-stage funding from the National Cancer Institute (NCI) allowed them to open their Research and Development facilities in the heart of New York City to develop novel targeted cancer diagnostics.

Terran Biosciences is a biotech platform company devoted to the development of therapeutics and technologies for patients with neurological and psychiatric diseases. Their portfolio includes a late-stage therapy for schizophrenia, late-stage selective serotonin 2A receptor antagonists, a drug design engine that has enabled first-in-class and best-in-class psychedelic therapies, and an AI-enabled imaging software platform.

Eight and a half million Americans live with non-healing wounds. Caring for these conditions unfortunately relies heavily on guesswork and approximations, perpetuating expensive and ineffective treatments. Care providers simply do not have the tools necessary to accurately track wound healing over time. Tissue Analytics is bringing wound care into the 21st century by turning the common smartphone into a sophisticated imaging platform. Tissue Analytics has developed proprietary image analysis algorithms that completely standardize wound documentation, allowing clinicians to make more informed decisions and heal patients faster.

Trace Biosciences is creating imaging agents for surgery. Our mission is to revolutionize surgery by highlighting detailed anatomy in real-time. Our first product is a nerve targeting imaging agent that will prevent surgical nerve damage. Nerve injury is a feared surgical complication affecting 25 million patients annually and incurring undue pain, loss of function, and high cost for follow on treatment and pain management. Currently, surgeons are entirely unassisted in nerve identification and preservation, relying solely on naked eye visualization or anatomical knowledge. If we can successfully develop this, our imaging agents will be used in almost all operating theaters, enable true precision surgery, and vastly improve patient outcomes. We are well funded through non-dilutive grants (SBIR, STTR + regional government) as well as venture capital investments. Founded in 2019 we are now developing our first products that will enter clinical trials in 2023.

Trice Medical™ was founded to fundamentally improve orthopedic diagnostics for the patient, physician, and payer by providing instant, eyes-on, answers. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physicians office. Our mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system.

TTI Medical specializes in video and digital camera adaptation onto surgical microscopes, ophthalmic slit lamps, and endoscopes. In addition, we are a distributor of Ikegami and Sony medical video cameras. We also manufacture various CO₂ laser accessories, fiberoptic handpieces, and re-usable suction/irrigation instruments. TTI Medical was established in 1984 with the mission of designing and marketing high quality, technologically advanced surgical instruments and medical devices. Our product design criteria must pass critical tests for performance, convenience, dependability, and cost containment. Product quality is held to the highest standards. Opportunities within the medical marketplace are constantly being identified and evaluated for new product development. Patents protect the proprietary technology utilized in the ACCU-Beam® and ACCU-Surg® product lines. The fundamental principal of “universality” is incorporated in each product design. Universality ensures the end user of maximum utilization at the lowest possible cost. Our philosophy of producing high quality reusable surgical devices focuses on the cost containment criteria required within the hospital managed care environment. Our quality policy is to provide products that satisfy the requirements of our customers including regulatory, design, and cost specifications. Products shall be produced under a management system in compliance with quality standards of ISO 13485:2016, FDA 21CFR820, and the European Medical Device Regulation 2017/745. Our policy is to be in compliance with all regulations that apply to the products in countries where our products are distributed. Products shall only be released if they conform to specifications without functional defect.

UroViu Corporation's mission is to revolutionize the cystoscopy platform for improved patient care and efficiency and has operations in California and Washington and production facilities in Asia. UroViu is the developer of the always ready cystoscopy platform, the most portable, self-contained and versatile single-use cystoscopy solution on the market. The intuitive portable platform and product suite are protected by a portfolio of 13 granted and many more pending patents. UroViu's vision is to simplify the scope of patient care.

Varex Imaging Corporation is the world’s largest independent supplier of medical X-ray tubes and image processing solutions. From medical imaging to cargo screening and border security, our components are used by X-ray imaging system manufacturers everywhere to detect, diagnose, and protect. Our products are designed to harness the power of X-ray energy to pioneer advances in any application. This requires us to maintain an extensive catalog, and we are a leading supplier of high-voltage connectors, X-ray collimators, ionization chambers, mammography paddles, solid state automatic exposure control systems and buckies for digital imaging. As a leader in imaging components, our goal is to help our customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster. Our rich history spans 65+ years of dedication to the imaging industry, but our everyday work is devoted to our partners’ success.

Our mission is to be the preferred therapeutic system for patients with reduced tissue perfusion. The Company has developed the first wearable therapeutic ultrasound device for the noninvasive, outpatient treatment of peripheral arterial disease. It is designed to promote vasodilation, collateral vessel growth and angiogenesis, and restore perfusion.

At ViewRay, our vision is clear: conquer cancer by re-envisioning radiation therapy., giving doctors new and better ways to treat their patients. ViewRay®, Inc. (NASDAQ:VRAY) shifts the paradigm in cancer treatment with the MRIdian® MRI-guided adaptive radiotherapy system. We're changing radiation therapy for the better with accurate, precise and personalized cancer treatment that no other system delivers, addressing the key limitations of existing external-beam radiation therapy technologies. Real-time imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian shapes the dose to fit the day. It's the only MR solution that enables fully integrated adaptive treatment with complete, on-table re-optimization of the daily treatment plan. It knows when to strike – and when to stop. MRIdian is the only RT solution with automated beam gating for precise and accurate dosing. When the tumor moves, the beam stops. The result? Better outcomes for patients. After seven years of clinical use, MRIdian has treated more than 12,500 patients worldwide. We're an innovative, entrepreneurial company with big ambitions, unlimited potential and a passion for a culture that is diverse and committed to our physicians and their patients. If you're ready to change the way the world views cancer, come join our team.

Founded in 2015, Visura is a medical device company dedicated to delivering state-of-art visualization solutions to improve the quality of transesophageal echocardiogram probe intubations. Visura has developed the TEECAD System, the world's first, FDA-cleared, disposable camera that seamlessly connects to a TEE probe, providing physicians real-time visualization for more efficient and effective probe placement.

ZOLL Medical is a medical devices company that specializes in healthcare technology for emergency response, with a focus on cardiac care and resuscitation.